BioSpace News Archive

Pluristem Therapeutics Inc., a leading biotechnology company, announced that it has received approval for an additional grant from the Israel Innovation Authority to support research based on its cutting-edge PLX platform.

Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), today announced financial results for the third quarter ended September 30, 2021 and highlighted recent corporate accomplishments.

Sotera Health Company, a leading global provider of mission-critical end-to-end sterilization solutions, lab testing and advisory services for the healthcare industry, announced financial results for the third quarter and first nine months of 2021.

PolarityTE, Inc. a biotechnology company developing regenerative tissue products and biomaterials, provided a business update and reported financial results for the three and nine-month periods ended September 30, 2021.

Prelude Corporation (PreludeDx™), announced today that the American Medical Association (AMA) has issued a new, dedicated Current Procedural Terminology (CPT®) Proprietary Laboratory Analyses (PLA) code for DCISionRT®, the only test available to predict personalized recurrence risk and radiation therapy benefit for patients with ductal carcinoma in situ (DCIS).

Evofem Biosciences, Inc., announced that it has submitted the registration for its hormone-free contraceptive vaginal gel to the Mexican Regulatory Agency COFEPRIS.

TheraCell Inc., a leading allograft solution company, today announced that it was selected as a recipient of the 2021 Spine Technology Award, presented by Orthopedics This Week at the North American Spine Society (NASS) meeting in Boston last month.

Chemomab Therapeutics, Ltd. (Nasdaq: CMMB) (Chemomab), today announced a poster presentation at The Liver Meeting® 2021, hosted by the American Association for the Study of Liver Diseases (AASLD), being held virtually November 12-15, 2021.

Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), announced today that it has been informed by the Israeli Innovation Authority (IIA) of the IIA’s decision to fund a second 18-month period of the CRISPR-IL consortium established last year.

Synlogic, Inc., a clinical-stage company bringing the transformative potential of synthetic biology to medicine, reported financial results for the third quarter ended September 30, 2021 and provided an update on clinical programs.